Released May 10, 2017, after the close
10-Q filed May 10, 2017, 40 days after period end · 0001144204-17-026034
Q1 2017 · 10-Q
Revenue$2.89M$2.89M +325.5% vs Q1 2016+38.8% vs Q4 2016
Net Income-$59.15M-$59.15M N/M vs Q1 2016N/M vs Q4 2016
EPS Diluted-$0.48-$0.48 N/M vs Q1 2016no prior Q4 2016 on file
Gross Profit$801,000+413.5%
Operating Income-$6,365,000N/M
Operating Cash Flow-$8,426,000N/M
Free Cash Flowderived-$8,646,000N/M
Margins · derived
Gross margin27.7%+4.8 pt vs Q1 2016
Operating margin-220.3%+937.9 pt vs Q1 2016
Net margin-2047.4%−781.1 pt vs Q1 2016
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2017 | Q1 2016 | Q1 2015 | Q1 2014 |
|---|---|---|---|---|
| Revenue | $2.89M | $679.00K | $1.69M | $6.70M |
| Net Income | -$59.15M | -$8.60M | -$5.97M | -$7.35M |
| EPS Diluted | -$0.48 | -$0.09 | -$0.06 | $0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR